JP2024525566A - Pd‐1抗体の医薬組成物及びその使用 - Google Patents

Pd‐1抗体の医薬組成物及びその使用 Download PDF

Info

Publication number
JP2024525566A
JP2024525566A JP2024500249A JP2024500249A JP2024525566A JP 2024525566 A JP2024525566 A JP 2024525566A JP 2024500249 A JP2024500249 A JP 2024500249A JP 2024500249 A JP2024500249 A JP 2024500249A JP 2024525566 A JP2024525566 A JP 2024525566A
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
retifanlimab
composition
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525566A5 (cg-RX-API-DMAC10.html
Inventor
サンパスクマール,クリシュナン
チョウ,ヤン
バーク,スティーブン,ジェームズ
Original Assignee
マクロジェニクス,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マクロジェニクス,インコーポレーテッド filed Critical マクロジェニクス,インコーポレーテッド
Publication of JP2024525566A publication Critical patent/JP2024525566A/ja
Publication of JP2024525566A5 publication Critical patent/JP2024525566A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2024500249A 2021-07-09 2022-06-22 Pd‐1抗体の医薬組成物及びその使用 Pending JP2024525566A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220006P 2021-07-09 2021-07-09
US63/220,006 2021-07-09
PCT/US2022/034493 WO2023283049A1 (en) 2021-07-09 2022-06-22 Pharmaceutical compositions of a pd-1 antibody and use of the same

Publications (2)

Publication Number Publication Date
JP2024525566A true JP2024525566A (ja) 2024-07-12
JP2024525566A5 JP2024525566A5 (cg-RX-API-DMAC10.html) 2025-06-30

Family

ID=82608118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500249A Pending JP2024525566A (ja) 2021-07-09 2022-06-22 Pd‐1抗体の医薬組成物及びその使用

Country Status (17)

Country Link
US (2) US12364756B2 (cg-RX-API-DMAC10.html)
EP (1) EP4366692A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024525566A (cg-RX-API-DMAC10.html)
KR (1) KR20240035533A (cg-RX-API-DMAC10.html)
CN (1) CN118215465A (cg-RX-API-DMAC10.html)
AR (1) AR126404A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022307332A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224640A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000077A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024000198A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240065A (cg-RX-API-DMAC10.html)
EC (1) ECSP24008791A (cg-RX-API-DMAC10.html)
IL (1) IL309985A (cg-RX-API-DMAC10.html)
MX (1) MX2024000268A (cg-RX-API-DMAC10.html)
PE (1) PE20240797A1 (cg-RX-API-DMAC10.html)
TW (1) TW202308694A (cg-RX-API-DMAC10.html)
WO (1) WO2023283049A1 (cg-RX-API-DMAC10.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476934C (en) * 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3705134A4 (en) * 2017-11-02 2021-07-28 Nanjing Shunxin Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
CN114206386A (zh) 2019-08-05 2022-03-18 小野药品工业株式会社 免疫检查点抑制剂的有效性判定生物标记

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Zynyz", EMA/CHMP/621679/2021, JPN6026024245, June 2021 (2021-06-01), ISSN: 0005883324 *

Also Published As

Publication number Publication date
KR20240035533A (ko) 2024-03-15
PE20240797A1 (es) 2024-04-18
CA3224640A1 (en) 2023-01-12
US20230025464A1 (en) 2023-01-26
AR126404A1 (es) 2023-10-11
EP4366692A1 (en) 2024-05-15
CR20240065A (es) 2024-04-08
TW202308694A (zh) 2023-03-01
AU2022307332A1 (en) 2024-01-18
US20250345422A1 (en) 2025-11-13
WO2023283049A1 (en) 2023-01-12
IL309985A (en) 2024-03-01
ECSP24008791A (es) 2024-03-01
MX2024000268A (es) 2024-01-31
US12364756B2 (en) 2025-07-22
CN118215465A (zh) 2024-06-18
CO2024000198A2 (es) 2024-02-05
CL2024000077A1 (es) 2024-08-23

Similar Documents

Publication Publication Date Title
JP7851889B2 (ja) Il-17抗体の医薬製品および安定した液体組成物
JP6759276B2 (ja) 抗vla1(cd49a)抗体医薬組成物
JP6396565B2 (ja) 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤
JP2022066345A (ja) 安定な抗ifnar1製剤
AU2013334740A1 (en) Stable, low viscosity antibody formulation
TWI609696B (zh) 包含抗-dll4抗體的穩定化調配物
EP3554543A2 (en) Stable aqueous anti-c5 antibody composition
US12364756B2 (en) Pharmaceutical compositions of a PD-1 antibody and use of the same
HK40112469A (en) Pharmaceutical compositions of a pd-1 antibody and use of the same
EA050933B1 (ru) Фармацевтические композиции антитела к pd-1 и применение указанной композиции
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
JP2024526773A (ja) B7‐h3抗体の医薬組成物及びその使用
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
CN116916952A (zh) HER2/neu抗体的药物组合物及其用途
HK40102521A (en) Pharmaceutical compositions of a her2/neu antibody and use of the same
HK40115478A (en) Aqueous formulations of an anti-cd22 antibody and uses thereof
WO2025140467A1 (zh) 稳定的高浓度抗pd-1抗体药物制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260611